260
Participants
Start Date
October 10, 2011
Primary Completion Date
October 15, 2015
Study Completion Date
October 15, 2015
US-ATG-F
20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
Placebo
250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
Royal Adelaide Hospital, Adelaide
Weill Cornell Medical Center, New York
Penn State Hershey Cancer Institute, Hershey
Abramson Cancer Center of the University at Perlman Center for Advanced Medicine, Philadelphia
University of North Carolina Hospitals, Chapel Hill
Duke University Medical Center, Durham
University of Florida Shands Cancer Center, Gainesville
Moffitt Cancer Center, Tampa
Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville
Mayo Clinic, Rochester
Loyola University Medical Center, Maywood
University of Chicago Medical Center, Chicago
Washington University Medical Center, St Louis
University of Kansas Medical Center, Westwood
Tulane University Health Sciences Center, New Orleans
University of Oklahoma Health Sciences Center, Oklahoma City
University of Texas Southwestern Medical Center, Dallas
Texas Transplant Physician's Group, San Antonio
University of Utah School of Medicine, Salt Lake City
City of Hope, Duarte
Stanford University Medical Center, BMT, Stanford
Oregon Health and Science University, Portland
VA Puget Sound Healthcare System, Seattle
Fred Hutchinson Cancer Research Center, Seattle
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston
Royal Melbourne Hospital, Parkville
Lead Sponsor
Neovii Biotech
INDUSTRY